← All trials
NCT04583228
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2020
- Primary completion
- Apr 10, 2021
- Completion date
- May 31, 2021
- First posted
- Oct 12, 2020
- Last posted
- Oct 14, 2020
- Enrollment
- 40
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hengenix Biotech IncLead sponsor
- ParexelOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.